ClinicalTrials.gg
RecruitingNCT07500090Updated Nov 13, 2026

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

A Phase 3 interventional study of HBS-301 tablet and Placebo in Idiopathic Hypersomnia, sponsored by Harmony Biosciences Management, Inc.. Recruiting at 54 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 13, 2026Site recruiting status changed14 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.

Planned enrollment
3rd of 27
248 · median 100
Started
2026
with 3 others
Phase 3
6 of 30
2 open now
Primary completion
2027-10
later than 6 of 12 live
Registered
28th of 30
by date
Lead sponsor
3 of 30
Harmony Biosciences Management, Inc.

Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 3rd largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 6 of the 12 other live ones, and was the 28th registered.

Idiopathic Hypersomnia

53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.

Browse Idiopathic Hypersomnia studies →

Open to participants now

12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Idiopathic Hypersomnia with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in adult participants (ages ≥18 years) with idiopathic hypersomnia (IH).

Read the detailed description

Approximately 248 participants are planned for randomization in the study. The study will consist of a Screening/Baseline Period (up to 28 days), a Double-blind Treatment Period (8 weeks), an optional Open-label Extension (OLE) Period (1 year), and 30 days of safety follow-up.

03

Conditions studied

  • Idiopathic Hypersomnia

Keywords

  • pitolisant
  • HBS-301
  • idiopathic hypersomnia
  • excessive daytime sleepiness
  • sleep inertia
  • fatigue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a current documented diagnosis of IH per the International Classification of Sleep Disorders, Third Edition (ICSD-3) or Text Revision (ICSD-3-TR) criteria with confirmatory polysomnogram (PSG) with multiple sleep latency test (MSLT; and if applicable, a 24-hour PSG report or an actigraphy report with sleep log) on file that led to the diagnosis and was completed within the last 10 years.
  • Has EDS.
  • Has moderate to very severe symptoms of IH.
  • If taking a permitted chronic concomitant medication or supplement, including nonprohibited antidepressants or wake-promoting agents, must be on a stable dose for at least 3 months prior to Screening and agree to continue at that stable dose for the Double-blind Treatment Period of the study. As-needed use of any treatment that could affect daytime sleepiness (including but not limited to stimulants, modafinil, and armodafinil) used on an as-needed basis is not permitted.

Exclusion criteria

Exclusion Criteria:

  • Has hypersomnia due to another medical disorder.
  • Has a history of pitolisant use within 5 half-lives prior to Screening.
  • Has a primary diagnosis of psychiatric illness, including depression, that is not well controlled.
  • Has a history of moderate or severe hepatic impairment.
  • Has a body surface area (BSA)-corrected estimated (eGFR) \<60 mL/min.
  • Has a known history of long syndrome or any significant history of a serious abnormality of the (ECG).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Double-Blind Treatment Period HBS-301

    HBS-301 tablets administered once daily in the morning upon wakening

    Drug: HBS-301 tablet

  • Placebo comparator
    Double-blind Treatment Period Placebo

    Matching placebo tablets administered once daily in the morning upon wakening

    Drug: Placebo

  • Experimental
    Open-label Extension Period HBS-301

    HBS-301 tablets administered once daily in the morning upon wakening

    Drug: HBS-301 tablet

Interventions

  • HBS-301 tablet

    Also known as: pitolisant delayed-release

  • DrugPlacebo

    Placebo tablet

06

What researchers measure

Primary outcomes

  1. Change in severity of EDS as measured by the Epworth Sleepiness Scale (ESS)

    The ESS is an 8-item, 4-point rating scale.

    Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)

Secondary outcomes

  1. Change in severity of IH symptoms as measured by the Idiopathic Hypersomnia Severity Scale (IHSS)

    The IHSS is a 14-item questionnaire designed to measure IH symptoms.

    Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)

  2. Change in sleep inertia as measured by the Sleep Inertia Questionnaire (SIQ)

    The SIQ is a 22-item questionnaire that measures aspects of night and day sleep symptoms and the sleep inertia related to each.

    Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)

  3. Change in fatigue as measured by the Patient-Reported Outcomes Measurement Information System Fatigue Short Form 7a

    The PROMIS-Fatigue-SF-7a is a 7-question, 5-point scale used to assess fatigue.

    Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)

  4. Change in severity of EDS as measured by the Epworth Sleepiness Scale

    The ESS is an 8-item, 4-point rating scale.

    Time frame: Baseline through Week 1 and Week 2 of the Titration Period (1 week and 2 weeks)

  5. Change in severity of IH symptoms as measured by the IHSS

    The ESS is an 8-item, 4-point rating scale.

    Time frame: Baseline through Week 1 and Week 2 of the Titration Period (1 week and 2 weeks)

  6. Change in severity of EDS as measured by the Clinical Global Impression of Severity (EDS)

    The Clinical Global Impression of Severity (EDS) is a 5-item observer-rated scale that gauges the severity of a participant's EDS symptoms.

    Time frame: Baseline to end of Double-blind Treatment Period (8 weeks)

  7. Change in severity of EDS as measured by the Patient Global Impression of Severity (EDS)

    The Patient Global Impression of Severity (EDS) is a participant-reported assessment that gauges the severity of a participant's EDS symptoms.

    Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)

  8. Improvement in severity of EDS as measured by the Patient Global Impression of Change (EDS)

    The Patient Global Impression of Change (EDS) is a participant-reported outcome used to evaluate the effectiveness of a treatment on their EDS symptoms.

    Time frame: End of the Double-blind Treatment Period (8 weeks)

  9. Change in severity of IH symptoms as measured by the Clinical Global Impression of Severity (IH)

    The Clinical Global Impression of Severity (IH) is a 3-item observer-rated scale used to track IH symptom changes.

    Time frame: Baseline to end of Double-blind Treatment Period (8 weeks)

  10. Change in severity of IH symptoms as measured by the Patient Global Impression of Severity (IH)

    The Patient Global Impression of Severity (IH) is a participant-reported assessment that gauges the severity of a participant's IH symptoms.

    Time frame: Baseline to end of Double-blind Treatment Period (8 weeks)

  11. Improvement in severity of IH symptoms as measured by the Patient Global Impression of Change (IH)

    The Patient Global Impression of Change (IH) is a participant-reported outcome used to evaluate the effectiveness of a treatment on their IH symptoms.

    Time frame: Baseline to end of Double-blind Treatment Period (8 weeks)

  12. Change in severity of sleep inertia as measured by the Patient Global Impression of Severity (Sleep Inertia)

    The Patient Global Impression of Severity (Sleep Inertia) is a participant-reported assessment that gauges the severity of a participant's sleep inertia symptoms.

    Time frame: Baseline to end of Double-blind Treatment Period (8 weeks)

  13. Improvement in severity of sleep inertia as measured by the Patient Global Impression of Change (Sleep Inertia)

    The Patient Global Impression of Change (Sleep Inertia) is a participant-reported outcome used to evaluate the effectiveness of a treatment on their sleep inertia symptoms.

    Time frame: End of the Double-blind Treatment Period (8 weeks)

  14. Change in severity of fatigue as measured by the Patient Global Impression of Severity (Fatigue)

    The Patient Global Impression of Severity (Fatigue) is a participant-reported assessment that gauges the severity of a participant's fatigue symptoms.

    Time frame: Baseline of the end of the Double-blind Treatment Period (8 weeks)

  15. Improvement in severity of fatigue as measured by the Patient Global Impression of Change (Fatigue)

    The Patient Global Impression of Change (Fatigue) is a participant-reported outcome used to evaluate the effectiveness of a treatment on their fatigue symptoms.

    Time frame: End of the Double-blind Treatment Period (8 weeks)

  16. Change in cognitive complaints as measured by the British Columbia Cognitive Complaints Inventory

    The British Columbia Cognitive Complaints Inventory is a participant-reported, 6-item, 4-point scale that assesses perceived cognitive difficulties.

    Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)

  17. Change in health-related quality of life as measured by the Short Form Health Survey-36 physical and mental component summaries

    The Short Form-36 includes 36 questions across 8 health domains to measure a participant's functional health and well-being.

    Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)

  18. Change in work productivity as measured by the Work Productivity and Activity Impairment: Idiopathic Hypersomnia Work Productivity loss score

    The Work Productivity and Activity Impairment: Idiopathic Hypersomnia questionnaire is a 6-item scale used to measure impairments over 7 days.

    Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)

  19. Incidence of treatment-emergent adverse events

    A treatment-emergent adverse event is any adverse event reported after the first dose of study drug and up to 30 days after final dose of study drug, or any worsening of a pre-existing condition reported after first dose of study drug and up to 30 days after final dose of study drug.

    Time frame: Throughout study (16 months including OLE)

07

Study locations

51 of 54 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2026
First posted
Mar 30, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites added, 2 sites removed. 2 sites changed recruiting status (1 now active, not recruiting, 1 now withdrawn)
Show 2 sites
  • Stern Research Partners, LLC · Huntersville, United StatesRecruiting→Active, not recruiting
  • Suburban Research Associates · West Chester, United StatesRecruiting→Withdrawn
Show 14 added (14 United States)
  • Springhill Medical Center · Mobile, United States
  • West Coast Pulmonary & Sleep Disorders Center · Lancaster, United States
  • University of California San Francisco · San Francisco, United States
  • PharmDev Clinical Research Institute, LLC · Miami, United States
  • Clinical Research Institute of Georgia LLC · Stockbridge, United States
  • OSF St Francis Medical Center · Peoria, United States
  • Boston Children's Hospital · Boston, United States
  • Henry Ford Medical Center · Novi, United States
  • Patient First MD · Middletown, United States
  • Northwell Health Physician Partners · New Hyde Park, United States
  • Research Carolina Elite LLC · Denver, United States
  • The University of Pittsburgh · Pittsburgh, United States
  • Medical University of South Carolina · Charleston, United States
  • DSM Research LLC · Frisco, United States
Show 2 removed
  • PharmDev Research Institute, LLC · Miami, United States
  • Clinical Research Institute Stockbridge · Stockbridge, United States
Nov 13, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Stern Research Partners, LLC · Huntersville, United StatesContact removed f•••@arsmnc.com · •••0090Contact removed (no phone or email listed)
  • David Kudrow, MD · Morrisville, United StatesContact •••3737→•••0719
  • Suburban Research Associates · West Chester, United StatesContact removed c•••@suburbanresearch.com · •••9024Contact removed (no phone or email listed)
  • Washington State University Sleep and Performance Center · Spokane, United StatesContact O•••@wsu.edu→s•••@wsu.edu
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    14 sites added, 2 sites removed. 2 sites changed recruiting status (1 now active, not recruiting, 1 now withdrawn)
    Show 2 sites
    • Stern Research Partners, LLC · Huntersville, United StatesRecruiting→Active, not recruiting
    • Suburban Research Associates · West Chester, United StatesRecruiting→Withdrawn
    Show 14 added (14 United States)
    • Springhill Medical Center · Mobile, United States
    • West Coast Pulmonary & Sleep Disorders Center · Lancaster, United States
    • University of California San Francisco · San Francisco, United States
    • PharmDev Clinical Research Institute, LLC · Miami, United States
    • Clinical Research Institute of Georgia LLC · Stockbridge, United States
    • OSF St Francis Medical Center · Peoria, United States
    • Boston Children's Hospital · Boston, United States
    • Henry Ford Medical Center · Novi, United States
    • Patient First MD · Middletown, United States
    • Northwell Health Physician Partners · New Hyde Park, United States
    • Research Carolina Elite LLC · Denver, United States
    • The University of Pittsburgh · Pittsburgh, United States
    • Medical University of South Carolina · Charleston, United States
    • DSM Research LLC · Frisco, United States
    Show 2 removed
    • PharmDev Research Institute, LLC · Miami, United States
    • Clinical Research Institute Stockbridge · Stockbridge, United States
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Stern Research Partners, LLC · Huntersville, United StatesContact removed f•••@arsmnc.com · •••0090Contact removed (no phone or email listed)
    • David Kudrow, MD · Morrisville, United StatesContact •••3737→•••0719
    • Suburban Research Associates · West Chester, United StatesContact removed c•••@suburbanresearch.com · •••9024Contact removed (no phone or email listed)
    • Washington State University Sleep and Performance Center · Spokane, United StatesContact O•••@wsu.edu→s•••@wsu.edu
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07500090
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Mar 16, 2026
Primary completion
Oct 2027 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Katie Wilmsen
Contact
clinicaltrials@harmonybiosciences.com
443-309-5556
Michelle Manuel
Contact
clinicaltrials@harmonybiosciences.com
847-903-4610
David Seiden, MD
study director · Harmony Biosciences Management, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBS-301

Start the discussion